Cargando…

Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease

The cholesterol absorption inhibitor ezetimibe can significantly reduce plasma cholesterol concentrations by inhibiting the Niemann-Pick C1-like 1 protein (NPC1L1), an intestinal sterol influx transporter that can actively facilitate the uptake of cholesterol for intestinal absorption. Unexpectedly,...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Bari, Ornella, Neuschwander-Tetri, Brent A., Liu, Min, Portincasa, Piero, Wang, David Q.-H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216277/ https://www.ncbi.nlm.nih.gov/pubmed/22132342 http://dx.doi.org/10.1155/2012/302847

Ejemplares similares

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Interactions between Bile Acids and Nuclear Receptors and Their Effects on Lipid Metabolism and Liver Diseases
por: Wang, David Q.-H., et al.
Publicado: (2012)

New insights into the role of Lith genes in the formation of cholesterol-supersaturated bile
por: Wang, Helen H., et al.
Publicado: (2017)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Recent advances in understanding and managing cholesterol gallstones
por: Di Ciaula, Agostino, et al.
Publicado: (2018)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Current Views on Genetics and Epigenetics of Cholesterol Gallstone Disease
por: Di Ciaula, Agostino, et al.
Publicado: (2013)

Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms
por: Mitten, Emilie K., et al.
Publicado: (2023)

The physical presence of gallstone modulates ex vivo cholesterol crystallization pathways of human bile
por: Portincasa, Piero, et al.
Publicado: (2019)

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
por: Lee, Hyo Young, et al.
Publicado: (2019)

Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease
por: Yilmaz, Yusuf, et al.
Publicado: (2014)

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
por: Di Ciaula, Agostino, et al.
Publicado: (2021)

Nonalcoholic fatty liver was associated with asymptomatic gallstones in a Chinese population
por: Qiao, Qiao-Hua, et al.
Publicado: (2017)

Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
por: Ahmed, Osman, et al.
Publicado: (2018)

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
por: Kleiner, David E., et al.
Publicado: (2019)

Critical Care Aspects of Gallstone Disease
por: Portincasa, Piero, et al.
Publicado: (2019)

Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease
por: Alsaif, Faisal A., et al.
Publicado: (2020)

Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease
por: Lyu, Jingting, et al.
Publicado: (2022)

An Inhibitor of Arginine‐Glycine‐Aspartate‐Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis
por: Ulmasov, Barbara, et al.
Publicado: (2018)

Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
por: Mukherjee, Sandip, et al.
Publicado: (2021)

Preventing a Mass Disease: The Case of Gallstones Disease: Role and Competence for Family Physicians
por: Portincasa, Piero, et al.
Publicado: (2016)

Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study
por: Chang, Yoosoo, et al.
Publicado: (2018)

Nutrition and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol
por: Enjoji, Munechika, et al.
Publicado: (2012)

Remnant cholesterol and severity of nonalcoholic fatty liver disease
por: Huang, Hangkai, et al.
Publicado: (2023)

The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: An observational Study
por: Kim, Young-Kyu, et al.
Publicado: (2019)

Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple
por: Yuan, Liyun, et al.
Publicado: (2021)

Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests
por: Di Ciaula, Agostino, et al.
Publicado: (2021)

Gypenosides Prevent and Dissolve Cholesterol Gallstones by Modulating the Homeostasis of Cholesterol and Bile Acids
por: Zhuang, Qian, et al.
Publicado: (2022)

An Update on the Lithogenic Mechanisms of Cholecystokinin a Receptor (CCKAR), an Important Gallstone Gene for Lith13
por: Wang, Helen H., et al.
Publicado: (2020)

Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase
por: van der Veen, Jelske N., et al.
Publicado: (2017)

coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment
por: Clearfield, Elizabeth, et al.
Publicado: (2021)

Pathogenesis of Cholesterol Gallstones
por: Strasberg, Steven M., et al.
Publicado: (1991)

Gallstone disease and nonalcoholic fatty liver disease in patients with type 2 diabetes: a cross-sectional study
por: Lu, Ye, et al.
Publicado: (2021)

Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease
por: Du, Tingting, et al.
Publicado: (2017)

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
por: Enjoji, Munechika, et al.
Publicado: (2010)

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
por: Lee, Na Young, et al.
Publicado: (2021)

Are Dietary Cholesterol Intake and Serum Cholesterol Levels Related to Nonalcoholic Fatty Liver Disease in Obese Children?
por: Papandreou, Dimitrios, et al.
Publicado: (2012)

Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008)

Nonalcoholic Fatty Liver Disease: Role of Medical Colleges in its Prevention and Control
por: Nath, Bhola, et al.
Publicado: (2022)

Enhancing Hepatic MBOAT7 Expression in Mice With Nonalcoholic Steatohepatitis
por: Sharpe, Martin C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6i8ovv7kdg8e3d17qtdo54ibqh